Research & development increased 22.5%
Research & development changed +22.5% from the comparable as-filed period.
$79.1M→$96.9M2 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →S financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Stock-based compensation increased 24.7%
Stock-based compensation changed +24.7% from the comparable as-filed period.
$73.9M→$92.1M2 prior comparisons
Working capital / assets moved 810 bp lower
Working capital / assets changed -810 basis points from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
21.10%→13.00%4 prior comparisons
Capital expenditure decreased 73.5%
Capital expenditure changed -73.5% from the comparable as-filed period.
$264,000→$70,0003 prior comparisons
Gross profit increased 15.8%
Gross profit changed +15.8% from the comparable as-filed period.
$181.7M→$210.4M2 prior comparisons
SBC / revenue moved 104 bp higher
SBC / revenue changed +104 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
30.51%→31.55%2 prior comparisons
Operating cash-flow margin moved 181 bp lower
Operating cash-flow margin changed -181 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
-0.43%→-2.24%2 prior comparisons
Current assets decreased 8.6%
Current assets changed -8.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$1.1B→$998.3M4 prior comparisons
Free-cash-flow margin moved 173 bp lower
Free-cash-flow margin changed -173 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
-0.54%→-2.27%2 prior comparisons
Capex / revenue moved 9 bp lower
Capex / revenue changed -9 basis points from the comparable as-filed period.
0.11%→0.02%2 prior comparisons
Receivables / revenue moved 126 bp higher
Receivables / revenue changed +126 basis points from the comparable as-filed period.
74.05%→75.31%2 prior comparisons
R&D / revenue moved 52 bp higher
R&D / revenue changed +52 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
32.66%→33.18%2 prior comparisons
Total assets increased 1.3%
Total assets changed +1.3% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$2.4B→$2.4B4 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.